Onychomycosis (Tinea Unguium) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Onychomycosis Pipeline Drugs Market Overview

Onychomycosis (Tinea Unguium) pipeline research report provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects.

Key Targets in the Onychomycosis Pipeline Market

The key targets in the onychomycosis pipeline market are Squalene Monooxygenase, Cell Membrane, Lanosterol 14 Alpha Demethylase, Cell Wall, and Ergosterol. Squalene Monooxygenase has the highest number of pipeline products in the onychomycosis pipeline market.

Onychomycosis Pipeline Market, by Targets

Onychomycosis Pipeline Market, by Targets

For more target insights, download a free report sample

Key MoA in the Onychomycosis Pipeline Market

The key MoA in the onychomycosis pipeline market are Squalene Monooxygenase Inhibitor, Cell Membrane Disruptor, Lanosterol 14 Alpha Demethylase Inhibitor, Cell Wall Disruptor, and Ergosterol Inhibitor. Squalene Monooxygenase Inhibitor has the highest number of pipeline products.

Onychomycosis Pipeline Market, by MoA

Onychomycosis Pipeline Market, by MoA

For more MoA insights, download a free report sample

Key RoA in the Onychomycosis Pipeline Market

The key RoA in the onychomycosis pipeline market are topical, oral, cutaneous, intravenous, and nasal. Topical has the highest number of pipeline products in the onychomycosis pipeline market.

Onychomycosis Pipeline Market, by RoA

Onychomycosis Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Onychomycosis Pipeline Market

The key molecule types in the onychomycosis pipeline market are small molecule, biologic, peptide, and synthetic peptide. Small molecule has the highest number of pipeline products.

Onychomycosis Pipeline Market, by Molecule Type

Onychomycosis Pipeline Market, by Molecule Type

For more molecule type insights, download a free report sample

Key Companies in the Onychomycosis Pipeline Market

The key companies in the onychomycosis pipeline market are Kaken Pharmaceutical Co Ltd, Blueberry Therapeutics Ltd, Moberg Pharma AB, Acea Biotech Inc, Almirall SA 1, Amtixbio Co Ltd, and ASCIL Biopharm. Kaken Pharmaceutical Co Ltd has the highest number of pipeline products.

Onychomycosis Pipeline Market, by Companies

Onychomycosis Pipeline Market, by Companies

To know more about companies, download a free report sample

Market report overview

Key targets Squalene Monooxygenase, Cell Membrane, Lanosterol 14 Alpha Demethylase, Cell Wall, and Ergosterol
Key MoA Squalene Monooxygenase Inhibitor, Cell Membrane Disruptor, Lanosterol 14 Alpha Demethylase Inhibitor, Cell Wall Disruptor, and Ergosterol Inhibitor
Key RoA Topical, Oral, Cutaneous, Intravenous, and Nasal
Key molecule types Small Molecule, Biologic, Peptide, and Synthetic Peptide
Key companies Kaken Pharmaceutical Co Ltd, Blueberry Therapeutics Ltd, Moberg Pharma AB, Acea Biotech Inc, Almirall SA 1, Amtixbio Co Ltd, and ASCIL Biopharm

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Acea Biotech Inc
Almirall SA
Amtixbio Co Ltd
ASCIL Biopharm
Blueberry Therapeutics Ltd
CSA Biotechnologies LLC
DermBiont Inc
Exodos Life Sciences Limited Partnership
Hallux Inc
Hexima Ltd
Infextious Therapeutic
Kaken Pharmaceutical Co Ltd
Moberg Pharma AB
Mycovia Pharmaceuticals Inc
NAL Pharmaceuticals Ltd
Nektr Technologies Ltd
Novabiotics Ltd
Photonamic GmbH & Co KG
SaNOtize Research and Development Corp
TTY Biopharm Co Ltd
Turn Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Onychomycosis (Tinea Unguium) – Overview

Onychomycosis (Tinea Unguium) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Onychomycosis (Tinea Unguium) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Onychomycosis (Tinea Unguium) – Companies Involved in Therapeutics Development

Acea Biotech Inc

Almirall SA

Amtixbio Co Ltd

ASCIL Biopharm

Blueberry Therapeutics Ltd

CSA Biotechnologies LLC

DermBiont Inc

Exodos Life Sciences Limited Partnership

Hallux Inc

Hexima Ltd

Infextious Therapeutic

Kaken Pharmaceutical Co Ltd

Moberg Pharma AB

Mycovia Pharmaceuticals Inc

NAL Pharmaceuticals Ltd

Nektr Technologies Ltd

Novabiotics Ltd

Photonamic GmbH & Co KG

SaNOtize Research and Development Corp

TTY Biopharm Co Ltd

Turn Therapeutics Inc

Onychomycosis (Tinea Unguium) – Drug Profiles

A-31S – Drug Profile

Product Description

Mechanism Of Action

History of Events

aminolevulinic acid hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

Amphotericin B sodium – Drug Profile

Product Description

Mechanism Of Action

ATB-1651 – Drug Profile

Product Description

Mechanism Of Action

BB-0305 – Drug Profile

Product Description

Mechanism Of Action

History of Events

benzalkonium chloride + polyhexanide – Drug Profile

Product Description

Mechanism Of Action

DBI-001 – Drug Profile

Product Description

Mechanism Of Action

efinaconazole – Drug Profile

Product Description

Mechanism Of Action

History of Events

ELS-160 – Drug Profile

Product Description

Mechanism Of Action

IFX-103 – Drug Profile

Product Description

Mechanism Of Action

KP-607 – Drug Profile

Product Description

Mechanism Of Action

NAL-3210 – Drug Profile

Product Description

Mechanism Of Action

NORS-0791 – Drug Profile

Product Description

Mechanism Of Action

NP-213 – Drug Profile

Product Description

Mechanism Of Action

History of Events

onymed – Drug Profile

Product Description

Mechanism Of Action

oteseconazole – Drug Profile

Product Description

Mechanism Of Action

History of Events

P-3058 – Drug Profile

Product Description

Mechanism Of Action

History of Events

pezadeftide – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Disrupt Cell Membrane for Onychomycosis – Drug Profile

Product Description

Mechanism Of Action

History of Events

terbinafine hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

terbinafine hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

terbinafine hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

TTY-W – Drug Profile

Product Description

Mechanism Of Action

Onychomycosis (Tinea Unguium) – Dormant Projects

Onychomycosis (Tinea Unguium) – Discontinued Products

Onychomycosis (Tinea Unguium) – Product Development Milestones

Featured News & Press Releases

Jan 12, 2022: Hallux starts phase 2 clinical study of novel subungual gel for onychomycosis

Dec 23, 2021: The Medical Products Agency in Sweden will be reference member state for Moberg Pharma’s European registration application

Sep 22, 2021: Moberg Pharma receives approval from the EMA’s Paediatric Committee

Aug 24, 2021: China patent for pezadeftide granted ACCESS CHINA Biotech Forum presentation investor webinar on 2 September 2021

Jul 26, 2021: Hexima: Completion of enrolment in phase IIb clinical trial

Jul 15, 2021: Hexima: Presentation of Phase I/IIa study data at American Podiatric Medical Association (APMA) and Investor Webinar

Jul 14, 2021: Hexima: Grant of European Patent over HXP124

Jun 10, 2021: Moberg Pharma: Phase 3-results for MOB-015 published in JAAD

May 20, 2021: Hexima announces INN designation for HXP124

May 12, 2021: Hexima : Grant of Australian patent over HXP124

Apr 26, 2021: Hexima to present at American Podiatric Medical Association annual conference

Mar 10, 2021: Acceptance of Clenafin/Jublia (efinaconazole) for regulatory review in China

Jan 07, 2021: Updated timeline to phase IIb results

Oct 14, 2020: Moberg Pharma intends to submit a registration application in Europe in 2021

Sep 14, 2020: Launch of Jublia, a treatment for tinea unguium, in Macau

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Onychomycosis (Tinea Unguium), 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Onychomycosis (Tinea Unguium) – Pipeline by Acea Biotech Inc, 2022

Onychomycosis (Tinea Unguium) – Pipeline by Almirall SA, 2022

Onychomycosis (Tinea Unguium) – Pipeline by Amtixbio Co Ltd, 2022

Onychomycosis (Tinea Unguium) – Pipeline by ASCIL Biopharm, 2022

Onychomycosis (Tinea Unguium) – Pipeline by Blueberry Therapeutics Ltd, 2022

Onychomycosis (Tinea Unguium) – Pipeline by CSA Biotechnologies LLC, 2022

Onychomycosis (Tinea Unguium) – Pipeline by DermBiont Inc, 2022

Onychomycosis (Tinea Unguium) – Pipeline by Exodos Life Sciences Limited Partnership, 2022

Onychomycosis (Tinea Unguium) – Pipeline by Hallux Inc, 2022

Onychomycosis (Tinea Unguium) – Pipeline by Hexima Ltd, 2022

Onychomycosis (Tinea Unguium) – Pipeline by Infextious Therapeutic, 2022

Onychomycosis (Tinea Unguium) – Pipeline by Kaken Pharmaceutical Co Ltd, 2022

Onychomycosis (Tinea Unguium) – Pipeline by Moberg Pharma AB, 2022

Onychomycosis (Tinea Unguium) – Pipeline by Mycovia Pharmaceuticals Inc, 2022

Onychomycosis (Tinea Unguium) – Pipeline by NAL Pharmaceuticals Ltd, 2022

Onychomycosis (Tinea Unguium) – Pipeline by Nektr Technologies Ltd, 2022

Onychomycosis (Tinea Unguium) – Pipeline by Novabiotics Ltd, 2022

Onychomycosis (Tinea Unguium) – Pipeline by Photonamic GmbH & Co KG, 2022

Onychomycosis (Tinea Unguium) – Pipeline by SaNOtize Research and Development Corp, 2022

Onychomycosis (Tinea Unguium) – Pipeline by TTY Biopharm Co Ltd, 2022

Onychomycosis (Tinea Unguium) – Pipeline by Turn Therapeutics Inc, 2022

Onychomycosis (Tinea Unguium) – Dormant Projects, 2022

Onychomycosis (Tinea Unguium) – Dormant Projects, 2022 (Contd..1)

Onychomycosis (Tinea Unguium) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Onychomycosis (Tinea Unguium), 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Onychomycosis (Tinea Unguium) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Onychomycosis (Tinea Unguium) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Onychomycosis (Tinea Unguium) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.